Provided by Tiger Trade Technology Pte. Ltd.

Organogenesis Holdings Inc

1.63
-0.0900-5.23%
Pre-market: 1.60-0.0261-1.60%05:09 EDT
Volume:1.06M
Turnover:1.75M
Market Cap:209.68M
PE:-2.04
High:1.71
Open:1.70
Low:1.62
Close:1.72
52wk High:7.08
52wk Low:1.54
Shares:128.64M
Float Shares:61.06M
Volume Ratio:2.05
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8009
EPS(LYR):0.1500
ROE:-25.92%
ROA:-4.11%
PB:1.41
PE(LYR):10.87

Loading ...

Organogenesis completes FDA BLA submission for ReNu knee osteoarthritis therapy

Reuters
·
Apr 29

Organogenesis Completes Rolling Submission of Biologics License Application for Renu®

THOMSON REUTERS
·
Apr 29

Undiscovered Gems In The US Market Featuring 3 Promising Stocks

Simply Wall St.
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE -Virgin Galactic, Humana, Broadcom

Reuters
·
Apr 07

Organogenesis achieves primary endpoint in PuraPly study

TIPRANKS
·
Apr 07

Organogenesis says PuraPly AM diabetic foot ulcer trial meets 12-week closure endpoint

Reuters
·
Apr 07

Organogenesis Cleared to Begin Rolling BLA for ReNu Knee Osteoarthritis Therapy

MT Newswires Live
·
Apr 07

Organogenesis Announces Successful FDA Meeting And Plan To File BLA For Renu® For Knee Osteoarthritis Pain

Reuters
·
Apr 07

Organogenesis announces successful FDA meeting, plans to file BLA for ReNu

TIPRANKS
·
Apr 07

Organogenesis gets FDA go-ahead to begin rolling ReNu BLA filing for knee OA

Reuters
·
Apr 07

Organogenesis Holdings Inc - Bla Submission for Renu Expected by End of 2025

THOMSON REUTERS
·
Apr 07

Organogenesis Announces Successful FDA Meeting and Plan to File Bla for Renu® for Knee Osteoarthritis Pain

THOMSON REUTERS
·
Apr 07

Organogenesis to report fiscal Q1 results, host conference call after market close

Reuters
·
Apr 06

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

GlobeNewswire
·
Apr 06

Organogenesis Advances NuShield Trial in Tough-to-Heal Leg Ulcers: What Investors Should Watch

TIPRANKS
·
Apr 04

Organogenesis Holdings Price Target Maintained With a $8.00/Share by BTIG

Dow Jones
·
Mar 26

Organogenesis Director Michael Joseph Driscoll Acquires Common Shares

Reuters
·
Mar 12

Organogenesis Holdings (ORGO) Margin-Driven Profitability Shift Tests Revenue Concern Narratives

Simply Wall St.
·
Feb 28

Organogenesis Holdings Inc. Files Initial Beneficial Ownership Statement for Chief Accounting Officer Patrick McGuire

Reuters
·
Feb 28

BTIG Keeps Their Buy Rating on Organogenesis Holdings (ORGO)

TIPRANKS
·
Feb 27